Loading...
Keywords
Last Name
Institution
 Back to Details

Connection

J. Steven Leeder to Cytochrome P-450 CYP3A

This is a "connection" page, showing publications J. Steven Leeder has written about Cytochrome P-450 CYP3A.

 
Connection Strength
  
 
 
3.514
  
  1. Chapron BD, Dinh JC, Toren PC, Gaedigk A, Leeder JS. The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites. Drug Metab Dispos. 2020 11; 48(11):1113-1120.
    View in: PubMed
    Score: 0.747
  2. Vyhlidal CA, Bi C, Ye SQ, Leeder JS. Dynamics of Cytosine Methylation in the Proximal Promoters of CYP3A4 and CYP3A7 in Pediatric and Prenatal Livers. Drug Metab Dispos. 2016 07; 44(7):1020-6.
    View in: PubMed
    Score: 0.543
  3. Vyhlidal CA, Pearce RE, Gaedigk R, Calamia JC, Shuster DL, Thummel KE, Leeder JS. Variability in Expression of CYP3A5 in Human Fetal Liver. Drug Metab Dispos. 2015 Aug; 43(8):1286-93.
    View in: PubMed
    Score: 0.518
  4. Vyhlidal CA, Gaedigk R, Leeder JS. Nuclear receptor expression in fetal and pediatric liver: correlation with CYP3A expression. Drug Metab Dispos. 2006 Jan; 34(1):131-7.
    View in: PubMed
    Score: 0.267
  5. Shakhnovich V, Vyhlidal C, Friesen C, Hildreth A, Singh V, Daniel J, Kearns GL, Leeder JS. Decreased Pregnane X Receptor Expression in Children with Active Crohn's Disease. Drug Metab Dispos. 2016 07; 44(7):1066-9.
    View in: PubMed
    Score: 0.137
  6. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle KE, MacPhee IA. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015 Jul; 98(1):19-24.
    View in: PubMed
    Score: 0.130
  7. Stockmann C, Reilly CA, Fassl B, Gaedigk R, Nkoy F, Stone B, Roberts JK, Uchida DA, Leeder JS, Sherwin CM, Spigarelli MG, Yost GS, Ward RM. Effect of CYP3A5*3 on asthma control among children treated with inhaled beclomethasone. J Allergy Clin Immunol. 2015 Aug; 136(2):505-7.
    View in: PubMed
    Score: 0.128
  8. Zia H, Murray GI, Vyhlidal CA, Leeder JS, Anwar AE, Bui MM, Ahmed AA. CYP3A isoforms in Ewing's sarcoma tumours: an immunohistochemical study with clinical correlation. Int J Exp Pathol. 2015 Apr; 96(2):81-6.
    View in: PubMed
    Score: 0.127
  9. Lalan S, Abdel-Rahman S, Gaedigk A, Leeder JS, Warady BA, Dai H, Blowey D. Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population. Pediatr Nephrol. 2014 Oct; 29(10):2039-49.
    View in: PubMed
    Score: 0.121
  10. Stockmann C, Fassl B, Gaedigk R, Nkoy F, Uchida DA, Monson S, Reilly CA, Leeder JS, Yost GS, Ward RM. Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control. J Pediatr. 2013 Jun; 162(6):1222-7, 1227.e1-2.
    View in: PubMed
    Score: 0.110
  11. Li D, Gaedigk R, Hart SN, Leeder JS, Zhong XB. The role of CYP3A4 mRNA transcript with shortened 3'-untranslated region in hepatocyte differentiation, liver development, and response to drug induction. Mol Pharmacol. 2012 Jan; 81(1):86-96.
    View in: PubMed
    Score: 0.101
  12. Kang P, Liao M, Wester MR, Leeder JS, Pearce RE, Correia MA. CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile. Drug Metab Dispos. 2008 Mar; 36(3):490-9.
    View in: PubMed
    Score: 0.078
  13. Pearce RE, Uetrecht JP, Leeder JS. Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene. Drug Metab Dispos. 2005 Dec; 33(12):1819-26.
    View in: PubMed
    Score: 0.066
  14. Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP, Pearce RE. Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther. 2005 Aug; 314(2):626-35.
    View in: PubMed
    Score: 0.064
  15. Rogan PK, Svojanovsky S, Leeder JS. Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. Pharmacogenetics. 2003 Apr; 13(4):207-18.
    View in: PubMed
    Score: 0.056
  16. Lowry JA, Kearns GL, Abdel-Rahman SM, Nafziger AN, Khan IS, Kashuba AD, Schuetz EG, Bertino JS, van den Anker JN, Leeder JS. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther. 2003 Mar; 73(3):209-22.
    View in: PubMed
    Score: 0.056
  17. Pearce RE, Gotschall RR, Kearns GL, Leeder JS. Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 2001 Dec; 29(12):1548-54.
    View in: PubMed
    Score: 0.051
  18. Leeder JS. Pharmacogenetics and pharmacogenomics. Pediatr Clin North Am. 2001 Jun; 48(3):765-81.
    View in: PubMed
    Score: 0.049
  19. Ogungbenro K, Wagner JB, Abdel-Rahman S, Leeder JS, Galetin A. A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents. Eur J Clin Pharmacol. 2019 Sep; 75(9):1227-1235.
    View in: PubMed
    Score: 0.043
  20. Meier R, Bi C, Gaedigk R, Heruth DP, Ye SQ, Leeder JS, Fridley BL. Ontogeny-related pharmacogene changes in the pediatric liver transcriptome. Pharmacogenet Genomics. 2018 03; 28(3):86-94.
    View in: PubMed
    Score: 0.039
  21. Blake MJ, Abdel-Rahman SM, Pearce RE, Leeder JS, Kearns GL. Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res. 2006 Dec; 60(6):717-23.
    View in: PubMed
    Score: 0.018
  22. Pearce RE, Leeder JS, Kearns GL. Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun; 34(6):1035-40.
    View in: PubMed
    Score: 0.017
  23. Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther. 2003 Nov; 74(5):437-47.
    View in: PubMed
    Score: 0.015
  24. Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther. 2000 Oct; 68(4):375-83.
    View in: PubMed
    Score: 0.012
  25. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Gaedigk A, Bertino JS. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. Pharmacogenetics. 1999 Aug; 9(4):453-62.
    View in: PubMed
    Score: 0.011
  26. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ, Bertino JS. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther. 1998 Sep; 64(3):257-68.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.